TickerTalks
Browse all tickers →
TickerTalks›$ANIK
ANANIK

Anika Therapeutics, Inc.

$ANIK·$215M·Medical - Devices·Healthcare
$18.07+11.8%YTD+67.9%1Y+44.9%
Mentions · last 7 days
2026-07-23: 0 posts2026-07-24: 0 posts2026-07-25: 0 posts2026-07-26: 0 posts2026-07-27: 0 posts2026-07-28: 0 posts2026-07-29: 6 posts6
Price updated 4m ago·X counts updated 22h ago
ANANIK
$ANIKAnika Therapeutics, Inc.
$18.07+11.75%6 posts
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $ANIK.

Medical - Devices · Healthcare

No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.

Industry benchmark

19-name peer basket
-8.8%YTD
-1.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-60.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-3.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-4.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
0.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-2.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
62.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$0.42$0.03+1300.0%
Q1 2026Apr 29, 2026$0.27$-0.07+485.7%
Q4 2025Feb 26, 2026$0.31$-0.13+348.0%
Q3 2025Nov 5, 2025$0.04$0.02+100.0%
Next earningsWed, Nov 4·consensus EPS $0.03

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$32.6M+15.6%65.1%9.1%$0.24$-2.1M
Q1 FY26$29.6M+13.2%64.2%-18.5%$-0.37$-6.3M
Q4 FY25$30.6M-2473.3%62.6%2.1%$0.02$4.0M
Q3 FY25$27.8M-28.2%56.0%-11.6%$-0.16$5.0M

Forward consensus

3-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$118.6M$118.5M – $118.7M-$0.12-$0.12 – -$0.122
FY27$126.6M$125.6M – $127.6M$0.15$0.15 – $0.162
FY28$133.6M$133.1M – $134.1M$0.66$0.66 – $0.661

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.84%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+7.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+30.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 12.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.235-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMay 1John B HennemanDirector5.0K sh$73KBuyApr 30Stephen D. GriffinCEO12.2K sh$150K
+ 27 other (11 awards · 8 exempts · 8 inkinds) in window

See when $ANIK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 148-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

Anika Therapeutics, Inc. entered into a Fifth Amendment to its Credit Agreement on July 10, 2026, amending the existing revolving line of credit established with Bank of America, N.A. in October 2017 and previously amended four times. The amendment modifies the terms and extends the maturity of the $50 million revolving credit facility through July 2031, providing Anika with continued access to working capital and financial flexibility as it executes its orthobiologics portfolio strategy. The credit facility is used to fund operations, product development, and potential business development activities. The amendment terms and the full credit agreement text are included as exhibits to the Form 8-K filed on July 14, 2026.

8-KOfficer or director changeJun 238-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Anika Therapeutics, Inc. held its annual meeting of stockholders on June 23, 2026, at which shareholders approved a sixth amendment and restatement of the company's 2017 Omnibus Incentive Plan, adding 350,000 shares to the pool available for equity-based compensation awards. The Board had adopted the amendment on April 26, 2026 subject to stockholder approval, and the meeting vote formally authorized the expanded equity plan. The filing also covers any director elections, auditor ratification, and other routine annual meeting proposals under Items 5.02 and 5.07. Adding 350,000 shares to the incentive plan replenishes the equity compensation pool for employee retention and performance grants going forward.

8-KOfficer or director changeApr 298-K — Item 2.02: Earnings release · Item 5.02: Officer or director change
8-KOfficer or director changeFeb 268-K — Item 2.02: Earnings release · Item 5.02: Officer or director change
+ 13 other (4 proxys · 3 13Gs · 2 10-Qs · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcriptseekingalpha.com·1d agoAnika Therapeutics Q2 Earnings Call Highlightsmarketbeat.com·1d agoAnika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026globenewswire.com·15d agoAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·55d agoBullish On Anika Therapeutics's Pullback As Integrity Scalesseekingalpha.com·91d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ISRG$MDT$BSX$BIO$EW$TMDX$ABT$NVCR
Voices on X · last 7 days

No standout posts about $ANIK on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport